U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT07462130) titled 'An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED)' on Feb. 22.
Brief Summary: Multicentre, Phase Ib/II Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of NTB003 in Participants with Thyroid Eye Disease
Study Start Date: March 01
Study Type: INTERVENTIONAL
Condition:
Thyroid Eye Disease
Intervention:
DRUG: NTB003
NTB003 dose 1 administered SC injection every 4 weeks.
DRUG: NTB003
NTB003 dose 2 administered SC injection every 4 weeks.
DRUG: NTB003
NTB003 dose 3 administered SC injection every 4 weeks.
DRUG: NTB003 and Placebo
Drug:NTB003 subcutan...